| U.S. Brand Names |
| A.P.L.®; Chorex®; Choron®; Gonic®; Pregnyl®; Profasi® HP |
 |
| Generic Available |
|
Yes |
|
| Synonyms |
| CG; hCG |
|
| Pharmacological Index |
|
Ovulation Stimulator |
|
| Use |
|
Induces ovulation and pregnancy in anovulatory, infertile females; treatment of hypogonadotropic hypogonadism, prepubertal cryptorchidism |
|
| Pregnancy Risk Factor |
|
C |
|
| Contraindications |
|
Hypersensitivity to chorionic gonadotropin or any component; precocious puberty, prostatic carcinoma or similar neoplasms |
|
| Warnings/Precautions |
|
Use with caution in asthma, seizure disorders, migraine, cardiac or renal disease; not effective in the treatment of obesity |
|
| Adverse Reactions |
|
1% to 10%: Central nervous system: Mental depression, fatigue Endocrine & metabolic: Pelvic pain, ovarian cysts, enlargement of breasts, precocious puberty Local: Pain at the injection site Neuromuscular & skeletal: Premature closure of epiphyses <1%: Peripheral edema, irritability, restlessness, headache, ovarian hyperstimulation syndrome, gynecomastia |
|
| Drug Interactions |
|
No data reported |
|
| Stability |
|
Following reconstitution with the provided diluent, solutions are stable for 30-90 days, depending on the specific preparation, when stored at 2°C to 15°C |
|
| Mechanism of Action |
|
Stimulates production of gonadal steroid hormones by causing production of androgen by the testis; as a substitute for luteinizing hormone (LH) to stimulate ovulation |
|
| Pharmacodynamics/Kinetics |
|
Half-life, biphasic: Initial: 11 hours; Terminal: 23 hours Elimination: Excreted unchanged in urine within 3-4 days |
|
| Usual Dosage |
|
I.M.: Prepubertal cryptorchidism: 1000-2000 units/m2/dose 3 times/week for 3 weeks OR 4000 units 3 times/week for 3 weeks OR 5000 units every second day for 4 injections OR 500 units 3 times/week for 4-6 weeks Hypogonadotropic hypogonadism: 500-1000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks OR 1000-2000 units 3 times/week OR 4000 units 3 times/week for 6-9 months; reduce dosage to 2000 units 3 times/week for additional 3 months Adults: Induction of ovulation: 5000-10,000 units one day following last dose of menotropins |
|
| Administration |
|
Give I.M. only |
|
| Reference Range |
|
Depends on application and methodology; <3 mIU/mL (SI: <3 units/L) usually normal (nonpregnant) |
|
| Mental Health: Effects on Mental Status |
|
May cause drowsiness or depression; rarely may cause restlessness or irritability |
|
| Mental Health: Effects on Psychiatric Treatment |
|
None reported |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Discontinue immediately if possibility of pregnancy |
|
| Dosage Forms |
|
Powder for injection (human origin): 200 units/mL (10 mL, 25 mL); 500 units/mL (10 mL); 1000 units/mL (10 mL); 2000 units/mL (10 mL) |
|
|
Copyright © 2007 Drugs Area |
